New pharmacotherapy for stroke prevention in atrial fibrillation: Update 2010

Advances in Therapy

Volumn 26, Issue 12, 2009, Pages 1058-1071

  Armaganijan, Luciana ^a   Eikelboom, John ^a   Healey, Jeff S ^a   Morillo, Carlos A ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Anticoagulation; Atrial fibrillation; Thrombin; Vitamin K antagonists

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; AMIODARONE; ANTICOAGULANT AGENT; ANTIFUNGAL AGENT; ANTIVITAMIN K; APIXABAN; AZD 0837; BETRIXABAN; CLOPIDOGREL; DABIGATRAN ETEXILATE; EDOXABAN; ENOXAPARIN; IDRABIOTAPARINUX; IDRAPARINUX; IRBESARTAN; MACROLIDE; PROTEINASE INHIBITOR; RIVAROXABAN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; WARFARIN; XIMELAGATRAN; YM 150;

ACUTE CORONARY SYNDROME; ANTICOAGULATION; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; LIVER TOXICITY; MORBIDITY; MORTALITY; REVIEW; RISK FACTOR; RISK REDUCTION; STROKE; THROMBOCYTE ACTIVATION; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; ATRIAL FIBRILLATION; FACTOR XA; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; THROMBIN; VITAMIN K;

EID: 77953019736     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12325-009-0084-8     Document Type: Review

References (47)

1. Ostrander LD Jr., Brandt RL, Kjelsberg MO, Epstein FH. Electrocardiographic findings among the adult population of a total natural community, Tecumseh, Michigan. Circulation. 1965; 31: 888-898.
2. Flegel KM, Shipley MJ, Rose G. Risk of stroke in nonrheumatic atrial fibrillation. Lancet. 1987; 1: 526-529.
3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham study. Stroke. 1991; 22: 983-988.
4. Furberg CD, Psaty BM, Manolio TA, et al. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol. 1994; 74: 236-241.
5. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA. 2001; 285: 2370-2375.
6. Gage BF, van Walraven C, Pearce L, et al. Selecting patients with atrial fibrillation for anticoagulation: Stroke risk stratification in patients taking aspirin. Circulation. 2004; 110: 2287-2292.
7. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007; 146: 857-867.
8. Nieuwlatt R, Capucci A, Lip GYH, et al. Antithrombotic treatment in real-life atrial fibrillation patients: A report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2006; 27: 3018-3026.
9. Hylek EM, D'Antonio J, Evans-Molina C, Shea C, Henault LE, Regan S. Translating the results of randomized trials into clinical practice: The challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation. Stroke. 2006; 37: 1075-1080.
10. Birman-Deych E, Radford MJ, Nilasena DS, Gage BF. Use and effectiveness of warfarin in medicare beneficiaries with atrial fibrillation. Stroke. 2006; 37: 1070-1074.
11. Waldo AL, Becker RC, Tapson VF, Colgan KJ, for the NABOR Steering Committee. Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. J Am Coll Cardio. 2005; 46: 1729-1736.
12. Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, Singer DE. Warfarin use among ambulatory patients with non-valvular atrial fibrillation: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Ann Intern Med. 1999; 131: 927-934.
13. Bungard TJ, Ghali WA, Teo KK, McAlister FA, Tsuyuki RT. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med. 2000; 160: 41-46.
14. Bradley BC, Perdue KS, Tisdel KA, Gilligan DM. Frequency of anticoagulation for atrial fibrillation and reasons for its non-use at a Veterans Affairs medical center. Am J Cardiol. 2000; 85: 568-572.
15. Connolly SJ, Eikelboom J, O'Donnell M, Pogue J. Yusuf S. Challenges of establishing new antithrombotic therapies in atrial fibrillation. Circulation 2007; 116: 449-455.
16. Albers GW, Dalen JE, Laupacis A, Manning WJ, Petersen P, Singer DE. Antithrmbotic therapy in atrial fibrillation. Chest. 2001; 119: 194S-1206S.
17. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with non-rheumatic atrial fibrillation. N Engl J Med. 1996; 335: 540-546.
18. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet. 2001; 358: 527-533.
19. Active Steering Committee, ACTIVE Investigators, Connolly S, et al. Rationale and design of ACTIVE: The atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events. Am Heart J. 2006; 151: 1187-1193.
20. ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): A randomized controlled trial. Lancet. 2006; 367: 1903-1912.
21. ACTIVE Investigators, Connolly SJ, Pogue J, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009; 360: 2066-2078.
22. Sobieraj-Teague M, O'Donnell M, Eikelboom J. New anticoagulants for atrial fibrillation. Semin Thromb Hemost. 2009; 35: 515-524.
23. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. Subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: The RE-MODEL randomized trial. J Thromb Haemost. 2007; 5: 2178-2185. (Pubitemid 47617868)
24. AMADEUS Investigators. Bousser MG, Bouthier J, et al. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: A randomised, open-label, non-inferiority trial. Lancet. 2008; 371: 315-321.
25. Olsson SB, Executive Steering Committee of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): Randomized controlled trial. Lancet. 2003; 362: 1691-1698.
26. Albers GW, Diener HC, Frison L, et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: A randomized trial. JAMA. 2005; 293: 690-698.
27. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: A randomised, double-blind, non-inferiority trial. Lancet. 2007; 370: 949-956. (Pubitemid 47393577)
28. RE-MOBILIZE Writing Committee, Ginsberg JS, Davidson BL, et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009; 24: 1-9.
29. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361: 1139-1151.
30. Lip GY, Rasmussen LH, Olsson SB, et al. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: A randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. Vitamin K antagonists. Eur Heart J. 2009; 30: 2897-2907.
31. Finsterer J, Stöllberger C. Strategies for primary and secondary stroke prevention in atrial fibrillation. Neth J Med. 2008; 66: 327-333.
32. Kubitza D, Haas S. Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases. Expert Opin Investig Drugs. 2006; 15: 843-855.
33. Turpie AG. New oral anticoagulants in atrial fibrillation. Eur Heart J. 2008; 29: 155-165.
34. Koopman MMW, Büller HR. Short-and longacting synthetic pentasaccharides. J Intern Med. 2003; 254: 335-342.
35. Bijsterveld NR, Vink R, van Aken BE, et al. Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers. Br J Haematol. 2004; 124: 653-658.
36. Bijsterveld NR, Moons AH, Boekholdt SM, et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation. 2002; 106: 2550-2554.
37. Perzborn E, Strassburger J, Wilmen A, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct Factor Xa inhibitor. J Thromb Haemost. 2005; 3: 514-521.
38. Mueck W, Becka M, Kubitza D, Voith B, Zuehlsdorf M. Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban - an oral, direct factor Xa inhibitor - in healthy subjects. Int J Clin Pharmacol Ther. 2007; 45: 335-344.
39. Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur J Clin Pharmacol. 2005; 61: 873-880.
40. Haas S. New oral Xa and IIa inhibitors: Updates on clinical trials results. J Thromb Thrombolysis. 2008; 25: 52-60.
41. Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: A double-blind, randomised controlled trial. Lancet. 2008; 372: 31-39.
42. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008; 358: 2776-2786.
43. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008; 358: 2765-2775.
44. Pinto DJ, Orwat MJ, Koch S, et al. Discovery of 1-(4-methoxyphenyl)-7- oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4, 5, 6, 7-tetrahydro-1H-pyrazolo[3, 4-c] pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem. 2007; 50: 5339-5356.
45. Lassen MR, Gallus AS, Pineo GF, Raskob GE, and the ADVANCE-1 Investigators. Randomized doubleblind comparison of apixaban with enoxaparin for thromboprophylaxis after knee replacement: The ADVANCE-1 trial. Paper presented at: The American Society of Hematology 50th Annual Meeting and Exposition; December 6-9, 2008; San Francisco, CA, USA.
46. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet. 2009; 48: 1-22.
47. Weitz JI, Connolly SJ, Kunitada S, Jin J, Patel I. Randomized, parallel group, multicenter, multinational study evaluating safety of DU-176b compared with warfarin in subjects with non-valvular atrial fibrillation. Paper presented at: American Society of Hematology 50th Annual Meeting and Exposition; December 6-9, 2008; San Francisco, CA, USA.